Ask your doctor what changes are going to be made for new stroke survivors based on this. If you don't demand something be done your next stroke will have just as bad an outcome.
http://www.future-science.com/doi/abs/10.4155/cli.13.91
Tissue plasminogen activator is the only US FDA-approved therapy for
acute ischemic stroke treatment. There is a need for other therapies
such as neuroprotective agents that can be used in acute ischemic stroke
patients. Many neuroprotective agents have been shown to be promising
after testing in animal models of acute stroke, but when tested in
patients, efficacy signals are not consistent or safety challenges have
been noted.
(This is exactly what Dr. Michael Tymianski,
a senior scientist at Toronto Western Research Institute talked about years ago.
This is probably why the 1000 studies that worked in rodents but failed in humans)
This review article will discuss different neuroprotective
agents, including free-radical scavengers and antioxidants,
NMDA-receptor antagonists, inflammatory cascade inhibitors and different
ion channel blockers/modulators that have been tested in acute ischemic
stroke. The review will also address the key reasons for their failure
in clinical trials and provide recommendations to improve translation of
basic science research into day-to-day clinical practice.
No comments:
Post a Comment